Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) has shared an announcement.
On October 15, 2025, Palisade Bio, Inc. announced it had $133.3 million in cash and cash equivalents, with 133,002,572 shares of common stock and pre-funded warrants for 73,271,424 shares outstanding. The company also received a compliance letter from Nasdaq confirming it had regained compliance with the minimum bid price requirement, closing a matter that began with a notice on April 30, 2025, regarding its stock price falling below $1.00 per share.
The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Palisade Bio, Inc. operates in the biotechnology industry, focusing on developing therapies for gastrointestinal diseases.
Average Trading Volume: 7,760,616
Technical Sentiment Signal: Sell
Current Market Cap: $211.7M
For an in-depth examination of PALI stock, go to TipRanks’ Overview page.